Asia Business News | Monday, September 08, 2008
RSS 2.0  
Mesoblast Limited (ASX:MSB) Announce Research Note By ABN AMRO Equities Australia

Melbourne, May 5, 2008 (ABN Newswire) - Mesoblast Limited (ASX:MSB)(US:MBLTY) Announce Research Note By ABN AMRO

Research note key outlook take-aways:

- MSB to accelerate Phase II spinal fusion trial

- Positive result of osteoarthritis trial

- Free upside from heart research

- Strong levels of cash

- Strong levels of IP protection

- Buy maintained, price target decreased to A$1.50

- Belief that MSB is most likely to partner with an orthopaedic firm to take MPCs to market.

- Should the technology prove scaleable, believe MSB may become an acquisition target for an orthopaedic company.

For the full report please visit the following link:
http://mesoblast.com/investor_analysis.php


About MESOBLAST LIMITED

Mesoblast Limited (ASX:MSB)(USOTC:MBLTY) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible.

Mesoblast has the worldwide exclusive rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has also acquired a substantial interest in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.

Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61 (03) 9639 6036
M: +61 (0) 419 228 128
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com


>>> MESOBLAST LIMITED
  
   MESOBLAST LIMITED  
   ABN NEWSWIRE